#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Adenoidně cystický karcinom slinných žláz.
Soubor 27 pacientů


Authors: L. Hauer 1;  A. Skálová 2,3;  P. Šteiner 3;  D. Hrušák 1;  P. Andrle 1;  L. Hostička 1;  O. Sebera 4
Authors‘ workplace: Stomatologická klinika LF UK a FN, Plzeň 1;  Šiklův ústav patologie LF UK a FN, Plzeň 2;  Bioptická laboratoř s. r. o., Plzeň 3;  ORL klinika LF UK a FN, Plzeň 4
Published in: Česká stomatologie / Praktické zubní lékařství, ročník 116, 2016, 3, s. 57-65
Category: Original Article – Retrospective Essay

Overview

Aim of the study:
Adenoid cystic carcinoma (AdCC) is the second most common salivary gland cancer. This malignant tumor is characterized by its slow growth and in spite of the fact that it has a histological low - grade appearance, a prolonged clinical course usually lasting for years, repeated recurrences, development of distant metastases and high mortality rate are typical signs. New facts of its biological behavior as well as new fusion oncogenes probably responsible for its carcinogenesis were described in the last few years. In light of these facts, the authors evaluate their own case series of patients suffering from AdCC in this manuscript.

Methods:
The retrospective case series included 27 patients with AdCC, who were treated at the University Hospital in Pilsen in the last 30 years (01/1986–01/2016). Clinical and demographic para-meters were identified and evaluated. Detection of the 1p36 deletion and the tumor-specific MYB–NFIB fusion oncogene by fluorescence in situ hybridization were performed.

Results:
The incidence of AdCC in minor salivary glands, submandibular gland, parotid gland and sublingual gland was 41%, 26%, 22 % and 11% respectively. The following staging was observed: the 1st stage in 26%, the 2nd stage in 18%, the 3rd stage in 26% and the 4th stage in 30% of cases. Metastases to regional lymph nodes were diagnosed in 26% and distant metastases in 30% of patients (55% to lung, 27% to liver, 9% to bones and 9% of peritoneal metastases). The average follow-up was 76.4 ± 67.0 months (range 7–287 months). An outcome of the treatment during follow-up was as follows: 59% of patients were with no evidence of the disease, 22% of patients died because of the disease and 19% of patients were alive with a recurrence or metastases of AdCC. The MYB-NFIB fusion transcript was detected in 79% of cases (19/24) and the 1p36 deletion in 13% of cases (3/23).

Conclusion:
The AdCC of salivary glands shows a greater tendency to development of regional lymph node metastases than previously thought. The MYB-NFIB gene fusion is the major tumor-specific oncogenic event in AdCC with high detection rate. The MYB-NFIB fusion oncogene could currently only be used as a potential diagnostic tool in difficult histopathological cases of AdCC, especially in late distant metastases.

Keywords:
adenoid cystic carcinoma – fusion oncogene – biomarker – MYB-NFIB


Sources

1. Agulnik, M., Cohen, E. W., Cohen, R. B., Chen, E. X., Vokes, E. E., Hotte, S. J., Winquist, E., Laurie, S., Hayes, D. N., Dancey, J. E., Brown, S., Pond, G. R., Lorimer, I., Daneshmand, M., Ho, J., Tsao, M. S., Siu, L. L.: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol., roč. 25, 2007, č. 25, s. 3978–3984.

2. Amit, M., Binenbaum, Y., Sharma, K., Ramer, N., Ramer, I., Agbetoba, A., Glick, J., Yang, X., Lei, D., Bjørndal, K., Godballe, C., Mücke, T., Wolff, K. D., Fliss, D., Eckardt, A. M., Copelli, C., Sesenna, E., Palmer, F., Ganly, I., Patel, S., Gil, Z.: Incidence of cervical lymph node metastasis and its association with outcomes in patients with adenoid cystic carcinoma. An international collaborative study. Head Neck, roč. 37, 2015, č. 7, s. 1032–1037.

3. Amit, M., Binenbaum, Y., Sharma, K., Ramer, N., Ramer, I., Agbetoba, A., Miles, B., Yang, X., Lei, D., Bjøerndal, K., Godballe, C., Mücke, T., Wolff, K. D., Fliss, D., Eckardt, A. M., Copelli, C., Sesenna, E., Palmer, F., Patel, S., Gil, Z.: Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study. Head Neck, roč. 36, 2014, č. 7, s. 998–1004.

4. Amit, M., Binenbaum, Y., Trejo-Leider, L., Sharma, K., Ramer, N., Ramer, I., Agbetoba, A., Miles, B., Yang, X., Lei, D., Bjørndal, K., Godballe, C., Mücke, T., Wolff, K. D., Eckardt, A. M., Copelli, C., Sesenna, E., Palmer, F., Ganly, I., Patel, S., Gil, Z.: International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck, roč. 37, 2015, č. 7, s. 1038–1045.

5. Amit, M., Na‘ara, S., Sharma, K., Ramer, N., Ramer, I., Agbetoba, A., Glick, J., Yang, X., Lei, D., Bjoerndal, K., Godballe, C., Mücke, T., Klaus-Dietrich, W., Eckardt, A. M., Copelli, C., Sesenna, E., Palmer, F., Ganly, I., Gil, Z.: Elective neck dissection in patients with head and neck adenoid cystic carcinoma: an international collaborative study. Ann. Surg. Oncol., roč. 22, 2015, č. 4, s. 1353–1359.

6. Barnes, L., Eveson, J. W., Reichart, P., Sidransky, D.: World Health Organization classification of tumours: Pathology and genetics of head and neck tumours. Lyon, IARC Press, 2005, s. 209–281.

7. Casler, J. D., Conley, J. J.: Surgical management of adenoid cystic carcinoma in the parotid gland. Otolaryngol. Head Neck Surg., roč. 106, 1992, č. 4, s. 332–338.

8. Ciccolallo, L., Licitra, L., Cantú, G., Gatta, G.; EUROCARE Working Group.: Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol., roč. 45, 2009, č. 8, s. 669–674.

9. Coca-Pelaz, A., Rodrigo, J. P., Bradley, P. J., Vander Poorten, V., Triantafyllou, A., Hunt, J. L., Strojan, P., Rinaldo, A., Haigentz, M. Jr., Takes, R. P., Mondin, V., Teymoortash, A., Thompson, L. D., Ferlito, A.: Adenoid cystic carcinoma of the head and neck – An update. Oral Oncol., roč. 51, 2015, č. 7, s. 652–661.

10. Ganly, I., Amit, M., Kou, L., Palmer, F.L., Migliacci, J., Katabi, N., Yu, C., Kattan, M. W., Binenbaum, Y., Sharma, K., Naomi, R., Abib, A., Miles, B., Yang, X., Lei, D., Bjoerndal, K.,Godballe, C., Mücke, T., Wolff, K. D., Fliss, D., Eckardt, A. M., Chiara, C., Sesenna, E., Ali, S., Czerwonka, L., Goldstein, D. P., Gil, Z., Patel, S. G.: Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study. Eur. J. Cancer, roč. 51, 2015, č. 18, s. 2768–2776.

11. Gao, M., Hao, Y., Huang, M. X., Ma, D. Q., Luo, H. Y., Gao, Y., Peng, X., Yu, G. Y.: Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int. J. Oral Maxillofac. Surg., roč. 42, 2013, č. 8, s. 923–928.

12. Hauer, L.: Dentoalveolární chirurgie. Test 10: Zhoubný nádor dutiny ústní – spinocelulární karcinom jazyka. LKS, roč. 25, 2015, č. 10, s. 203–207.

13. Hellquist, H., Skálová, A., Barnes, L., Cardesa, A., Thompson, L. D., Triantafyllou, A., Williams, M. D., Devaney, K. O., Gnepp, D. R., Bishop, J. A., Wenig, B .M., Suárez, C., Rodrigo, J. P., Coca-Pelaz, A., Strojan, P., Shah, J. P., Hamoir, M., Bradley, P.J., Silver, C. E., Slootweg, P. J., Vander Poorten, V., Teymoortash, A., Medina, J. E., Robbins, K. T., Pitman, K. T., Kowalski, L. P., de Bree, R., Mendenhall, W. M., Eloy, J. A., Takes, R. P., Rinaldo, A., Ferlito, A.: Cervical lymph node metastasis in high-grade transformation of head and neck adenoid cystic carcinoma: a collective international review. Adv. Ther., 2016 [Epub ahead of print].

14. Ho, A. L., Sherman, E. J., Fury, M. G., Baxi, S. S., Haque, S., Sima, C. S., Antonescu, C. R., Katabi, N., Pfister, D. G.: Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma. J. Clin. Oncol., roč. 32, 2014, č. 15, Suppl., s. 6093.

15. Chau, N. G., Hotte, S. J., Chen, E. X., Chin, S. F., Turner, S., Wang, L., Siu, L. L.: A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann. Oncol., roč. 23, 2012, č. 6, s. 1562–1570.

16. Keam, B., Kim, S. B., Shin, S. H., Cho, B. C., Lee, K. W., Kim, M. K., Yun, H. J., Lee, S. H., Yoon, D. H., Bang, Y. J.: Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer, roč. 121, 2015, č. 15, s. 2612–2617.

17. Kim, D. W., Oh, D. Y., Shin, S. H., Kang, J. H., Cho, B. C., Chung, J. S., Kim, H., Park, K. U., Kwon, J. H., Han, J. Y., Kim, M. J., Bang, Y. J.: A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer, roč. 14, 2014, s. 795.

18. Laurie, S. A., Ho, A. L., Fury, M. G., Sherman, E., Pfister, D. G.: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol., roč.12, 2011, č. 8, s. 815–824.

19. Li, N., Xu, L., Zhao, H., El-Naggar, A. K., Sturgis, E. M.: A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer, roč. 118, 2012, č. 16, s. 3945–3953.

20. Lin, Y. C., Chen, K. C., Lin, C. H., Kuo, K. T., Ko, J. Y., Hong, R. L.: Clinicopathological features of salivary and non-salivary adenoid cystic carcinomas. Int. J. Oral Maxillofac. Surg., roč. 41, 2012, č. 3, s. 354–360.

21. Locati, L. D., Bossi, P., Perrone, F., Potepan, P., Crippa, F., Mariani, L., Casieri, P., Orsenigo, M., Losa, M., Bergamini, C., Liberatoscioli, C., Quattrone, P., Calderone, R. G., Rinaldi, G., Pilotti, S., Licitra, L.: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol., roč. 45, 2009, č. 7, s. 574–578.

22. Marchiò, C., Weigelt, B., Reis-Filho, J. S.: Adenoid cystic carcinomas of the breast and salivary glands (or ‚The strange case of Dr Jekyll and Mr Hyde‘ of exocrine gland carcinomas). J. Clin. Pathol., roč. 63, 2010, č. 3, s. 220–228.

23. Marx, R. E., Stern, D.: Oral and maxillofacial pathology: A rationale for diagnosis and treatment. 2. vyd., Quintessence Pub. Co., 2012, s. 547 – 598.

24. Mendenhall, W. M., Morris, C. G., Amdur, R. J., Werning, J. W., Hinerman, R. W., Villaret, D. B.: Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck, roč. 26, 2004, č. 2, s. 154–162.

25. Min, R., Siyi, L., Wenjun, Y., Ow, A., Lizheng, W., Minjun, D., Chenping, Z.: Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. Int. J. Oral Maxillofac. Surg., roč. 41, 2012, č. 8, s. 952–957.

26. Mitani, Y., Liu, B., Rao, P. H., Borra, V. J., Zafereo, M., Weber, R. S., Kies, M., Lozano, G., Futreal, P. A., Caulin, C., El-Naggar, A. K.: Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin. Cancer Res., roč. 22, 2016, č. 3, s. 725–733.

27. Mitani, Y., Rao, P. H., Futreal, P. A., Roberts, D. B., Stephens, P. J., Zhao, Y. J., Zhang, L., Mitani, M., Weber, R. S., Lippman, S. M., Caulin, C., El-Naggar, A. K.: Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin. Cancer Res., roč. 17, 2011, č. 22, s. 7003–7014.

28. Myers, E. N., Ferris, R. L.: Salivary gland disorders. 1. vyd., Berlin, Springer-Verlag, 2007, s. 59–62.

29. Nagao, T.: „Dedifferentiation“ and high-grade transformation in salivary gland carcinomas. Head Neck Pathol., roč. 7, 2013, Suppl. 1, s. S37–S47.

30. Persson, M., Andrén, Y., Moskaluk, C. A., Frierson, H. F. Jr., Cooke, S. L., Futreal, P. A., Kling, T., Nelander, S., Nordkvist, A., Persson, F., Stenman, G.: Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer, roč. 51, 2012, č. 8, s. 805–817.

31. Rao, P. H., Roberts, D., Zhao, Y. J., Bell, D., Harris, C. P., Weber, R. S., El-Naggar, A. K.: Deletion of 1p32–p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin. Cancer Res., roč. 14, 2008, č. 16, s. 5181–5187.

32. Rettig, E. M., Tan, M., Ling, S., Yonescu, R., Bishop, J. A., Fakhry, C., Ha, P. K.: MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. Laryngoscope, roč. 125, 2015, č. 9, s. E292–E299.

33. Stenman, G., Persson, F., Andersson, M. K.: Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol., roč. 50, 2014, č. 8, s. 683–690.

34. Suárez, C., Barnes, L., Silver, C. E., Rodrigo, J. P., Shah, J. P., Triantafyllou, A., Rinaldo, A., Cardesa, A., Pitman, K. T., Kowalski, L. P., Robbins, K. T., Hellquist, H., Medina, J. E., de Bree, R., Takes, R. P., Coca-Pelaz, A., Bradley, P. J., Gnepp, D. R., Teymoortash, A., Strojan, P., Mendenhall, W. M., Eloy, J. A., Bishop, J. A., Devaney, K. O., Thompson, L. D. R., Hamoir, M., Slootweg, P. J., Vander Poorten, V., Williams, M. D., Wenig, B. M., Skálová, A., Ferlito, A.: Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review. Auris Nasus Larynx, 2016, článek v tisku.

35. Subramaniam, T., Lennon, P., O‘Neill, J. P.: Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Ir. J. Med. Sci., roč. 184, 2015, č. 3, s. 583–590.

Labels
Maxillofacial surgery Orthodontics Dental medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#